Lyell Immunopharma Inc (LYEL)
0.9478
+0.03
(+3.40%)
USD |
NASDAQ |
Nov 22, 16:00
0.9478
0.00 (0.00%)
After-Hours: 20:00
Lyell Immunopharma Enterprise Value: -184.61M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | -184.61M |
| November 20, 2024 | -152.95M |
| November 19, 2024 | -130.61M |
| November 18, 2024 | -130.61M |
| November 15, 2024 | -133.40M |
| November 14, 2024 | -133.40M |
| November 13, 2024 | -133.40M |
| November 12, 2024 | -115.26M |
| November 11, 2024 | -102.69M |
| November 08, 2024 | -99.90M |
| November 07, 2024 | -99.90M |
| November 06, 2024 | -27.30M |
| November 05, 2024 | -94.31M |
| November 04, 2024 | -114.67M |
| November 01, 2024 | -153.16M |
| October 31, 2024 | -194.14M |
| October 30, 2024 | -220.31M |
| October 29, 2024 | -197.27M |
| October 28, 2024 | -200.38M |
| October 25, 2024 | -202.69M |
| October 24, 2024 | -160.86M |
| October 23, 2024 | -145.46M |
| October 22, 2024 | -145.50M |
| October 21, 2024 | -153.20M |
| October 18, 2024 | -140.37M |
| Date | Value |
|---|---|
| October 17, 2024 | -137.80M |
| October 16, 2024 | -119.84M |
| October 15, 2024 | -140.37M |
| October 14, 2024 | -135.24M |
| October 11, 2024 | -137.80M |
| October 10, 2024 | -160.89M |
| October 09, 2024 | -163.46M |
| October 08, 2024 | -150.63M |
| October 07, 2024 | -150.63M |
| October 04, 2024 | -127.54M |
| October 03, 2024 | -135.24M |
| October 02, 2024 | -124.97M |
| October 01, 2024 | -112.15M |
| September 30, 2024 | -86.49M |
| September 27, 2024 | -104.55M |
| September 26, 2024 | -101.99M |
| September 25, 2024 | -145.51M |
| September 24, 2024 | -117.35M |
| September 23, 2024 | -125.03M |
| September 20, 2024 | -104.55M |
| September 19, 2024 | -91.75M |
| September 18, 2024 | -145.51M |
| September 17, 2024 | -135.27M |
| September 16, 2024 | -173.68M |
| September 13, 2024 | -176.24M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-231.76M
Minimum
Sep 20 2023
4.507B
Maximum
Jun 17 2021
617.92M
Average
168.48M
Median
Enterprise Value Benchmarks
| Chimerix Inc | -54.06M |
| NovaBay Pharmaceuticals Inc | 2.798M |
| Palatin Technologies Inc | 15.96M |
| iBio Inc | 12.31M |
| Theriva Biologics Inc | -12.68M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -44.58M |
| Revenue (Quarterly) | 0.034M |
| Total Expenses (Quarterly) | 50.54M |
| EPS Diluted (Quarterly) | -0.17 |
| Profit Margin (Quarterly) | -131.1K% |
| Earnings Yield | -83.35% |
| Normalized Earnings Yield | -77.96 |